Praecis Pharmaceuticals, Inc.

Provid Pharmaceuticals Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Rutgers, the State University of New Jersey

Immune Control Inc.

University of California

Hoffmann-la Roche Inc.

Sequenom, Inc.

Cognosci, Incorporated

Christopher Self

Gary Olson

Charles Michael Cook

Lily Lee

Jens Birktoft

Barry A Morgan

Christopher C Arico-Muendel

Richard H Ebright

Yves Pommier

Stephen A Roth

Yon W Ebright

Mark A Findeis

Kathryn Phillips

Robert H Shoemaker

Juan Shen

Michael Currens

Guangtao Zhang

Dominic Scudiero

John Cardellina

Clayton Buck

George Lountos

David Waugh

William Solvibile

Anne-Cecile Hiebel

James Bacci

Charles Cantor

Peter Mohr

Pierre Barbier

Andreas Braun

Marc Muller

Michael Peter Vitek

Susan S Taylor

Suzanne E McKenna

Stefan M Kammerer

Andrew Jobson

Andrew Vargha Colasanti

Andy Jobson

Sudhir Kondapaka

Gary L Olsen

Lora Burns-Hamuro

The invention provides compounds of formula Ia, Ib and Ic: and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.

Antibacterial agents: aryl myxopyronin derivatives

The invention provides compounds of formula la, lb and Ic: [Formula Ia, Ib, and Ic] and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.

A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: Gis a group of the formula or where n is 0, 1, 2, 3, or 4 and Het is a 5- or 6-membered heteroaryl group containing 1 to 4 heteroatoms independently chosen from N, O, and S, which Het is optionally substituted. 

Method of treating HCV infection with a small molecule CHK2 inhibitor

Provided herein are Compounds having the following structure: 

Kinase inhibitors, compositions thereof, and methods of use therewith

The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.

Inhibitors of antigen presentation by MHC class II molecules

Methods for the use of inhibitors of antigen presentation by MHC class II molecules

The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists.

Compositions for treatment of diseases related to activated lymphocytes

Novel ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including CNS inflammation, traumatic brain injury, cerebral ischema, Alzheimer's Disease and other brain disorders.

APO E analogs and methods for their use

Methods for treatment of diseases related to activated lymphocytes

Compounds that modulate natural &#x3b2; amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a &#x3b2; amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a &#x3b2; amyloid peptide, preferably a retro-inverso isomer of A&#x3b2;. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.

Modulators of &#x3b2;-amyloid peptide aggregation

Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof

A-kinase anchor protein (AKAPs) muteins, peptides thereof, and nucleic acids encoding the peptides are provided herein. Also provided are transgenic animals, cells comprising transgenes and various methods employing such peptides.

Kinase anchor protein muteins, peptides thereof and related documents

The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Therapeutic agents and methods of use thereof for the treatment of melanoma

The present invention provides methods of treating a lymphoma (e.g., a T-cell lymphoma or a B-cell lymphoma) in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention, for example, compounds of formulae I and XV: 

Methionine aminopeptidase-2 inhibitors and methods of use thereof

Therapeutic agents and methods of use thereof for the modulation of angiogenesis

Growing community of inventors

West Caldwell, NJ, United States of America

Christopher Self